Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

Nonetheless, the bottom line improved 14.1% from the year-ago quarter (up 16% in constant currency). The top line also increased 0.2% year over year and 2% in cc, which was within management’s guidance of 1-3% in cc.

Shares Down on Tepid Q2 Guidance

In the pre-market trading, shares of Oracle are down approximately 1.8%. The decline can be attributed to tepid fiscal second-quarter guidance and revenue miss in reported fiscal first quarter results.

Notably, for the fiscal second quarter, Oracle expects non-GAAP earnings per share to be 88-90 cents in cc (and 87-89 cents excluding currency impact). The Zacks Consensus Estimate for the same is pegged at 91 cents.

Markedly, Oracle stock has returned 26.3% year to date, underperforming the industry’s rally of 30.5%.

Top Line in Detail

Oracle reported total revenues (on a GAAP basis) of $9.218 billion, flat year over year (up 2% in cc).

Revenues by Offerings

Oracle’s top line benefited from the ongoing cloud-based momentum. Cloud services and license support revenues (74% of total revenues) for the reported quarter improved 3% year over year (up 4% in cc) to $6.805 billion.

Meanwhile, cloud license and on-premise license revenues (9% of total revenues) declined 6% year over year (down 6% in cc) to $812 million.

Hardware revenues (9% of total revenues) were $815 million, declining 10% (down 9% in cc) year over year.

Services revenues (8% of total revenues) decreased 3% to $786 million (down 2% in cc).

Revenues by Geography

Revenues from Americas (represented 55.9% of total revenues) were down 0.2% year over year to $5.150 billion.

Management announced that both NetSuite ERP and Fusion ERP businesses were up 33% in the fiscal first quarter. NetSuite ERP and Fusion ERP have customer strength of around 18,000 and 6,500, respectively. The expanding customer base is enabling the company to maintain its leading position in cloud ERP market.

Further, the next-generation autonomous database launched by Oracle, which is supported by ML, is gaining traction. In the reported quarter, Oracle added around 500 new Autonomous Database cloud customers. Management expects the count to grow more than twofold in fiscal second quarter. This is expected to be a key catalyst.

Oracle notes that it will roll out new Autonomous Cloud Services at its upcoming OpenWorld conference, with an aim to enhance Autonomous Database offering.

The company is making every effort to enhance functionalities of cloud-based applications, which is encouraging adoption. Moreover, the company is strategically expanding Autonomous Database portfolio by incorporating robust ML and AI capabilities.

These initiatives are expected to provide the company an edge in the Database-as-a-Service market and reinforce its competitive position against Amazon Web Services.

CEO Mark Hurd’s Medical Leave

Oracle announced that company’s CEO Mark V. Hurd “will take a leave of absence for health related reasons.”

Notably, Oracle has a co-CEO framework. During Hurd’s absence, company’s Chief Technology Officer and founder Larry Ellison, and co-CEO Safra Catz will take over Hurd's responsibilities.

The company hasn’t divulged details on the tenure of the leave.

Operating Details

Non-GAAP operating expenses, as a percentage of revenues, contracted 80 bps to 58.3%.

Non-GAAP operating income during the reported quarter was $3.84 billion, up 2.2% year over year.

Non-GAAP operating margin expanded 100 bps year over year and came in at 42%.

Balance Sheet & Cash Flow

As of Aug 31, 2019, Oracle had cash & cash equivalents, and marketable securities of $35.7 billion, down from $37.83 billion sequentially.

Long-term earnings growth rate for LogMeIn, Anixter and Perficient is currently pegged at 5%, 8% and 10.75%, respectively.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

Normally $25 each - click below to receive one report FREE:

Zacks' 7 Best Strong Buy Stocks for June, 2020

FREE Report Exclusively for Zacks.com Readers

In a new special report, Zacks experts have chosen 7 Zacks Rank #1 Strong Buy stocks out of 220. These stocks have the greatest potential to increase in price immediately. A recent pick, Activision Blizzard, is up 20% in 2020 and 25% since the market's lows of late March.

For more than 30 years, Zacks' private Strong Buy list has averaged returns that have more than doubled the market. Get your FREE special report now.

Client Support

Follow Us

Zacks Mobile App

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.52% per year. These returns cover a period from January 1, 1988 through May 4, 2020. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Visit performance for information about the performance numbers displayed above.

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service.